<p>Savara Inc.（纳斯达克代码：SVRA - 免费报告）- HC Wainwright 的股票分析师在 12 月 23 日（星期二）向投资者发布的报告中上调了对 Savara 2029 财年每股收益（EPS）的预期。HC Wainwright 分析师 A. Fein 现在预计该公司将发布每股收益 0.56 美元，高于之前预测的 0.51 美元。HC Wainwright 目前对该股票给予 “买入” 评级，目标价格为 10.00 美元。市场普遍预计 Savara 当前全年的每股收益为（0.45 美元）。</p>
<p>其他几家券商最近也对 SVRA 发表了看法。Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对 Savara 股票的 “卖出（d-）” 评级。瑞银集团在周二的研究报告中将 Savara 的目标价格设定为 10.00 美元。Guggenheim 在周二的研究报告中重申了对 Savara 股票的 “买入” 评级。富国银行在 12 月 18 日（星期四）的报告中将 Savara 的目标价格从 7.00 美元上调至 9.00 美元，并给予该股票 “超配” 评级。最后，Oppenheimer 在周二的研究报告中将 Savara 的目标价格设定为 10.00 美元。一位研究分析师对该股票给予了强烈买入评级，七位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价格为 9.13 美元。</p>
<p><strong>阅读我们最新的 SVRA 股票分析</strong></p>
<h2>Savara 股票表现</h2>
<p>周三，纳斯达克 SVRA 的股票开盘价为 6.44 美元。该股票的市值为 13.1 亿美元，市盈率为-12.15，贝塔值为 0.23。Savara 的 1 年最低价为 1.89 美元，1 年最高价为 7.01 美元。该公司的 50 日移动平均价格为 5.06 美元，200 日移动平均价格为 3.64 美元。公司的债务与股本比率为 0.32，流动比率为 7.65，速动比率为 7.65。</p>
<p>Savara（纳斯达克：SVRA - 获取免费报告）最后一次发布财报是在 11 月 12 日（星期三）。该公司报告的季度每股收益为（0.14 美元），低于市场共识预期的（0.13 美元）0.01 美元。</p>
<h2>机构投资者对 Savara 的看法</h2>
<p>大型投资者最近买入和卖出了该公司的股票。F m Investments LLC 在第二季度将其在 Savara 的持仓增加了 41.2%。F m Investments LLC 目前拥有 314,846 股该公司股票，价值 718,000 美元，此前在上个季度又购买了 91,830 股。Farther Finance Advisors LLC 在第二季度将其在 Savara 的持仓增加了 17.6%。Farther Finance Advisors LLC 目前拥有 38,001 股该公司股票，价值 87,000 美元，此前在上个季度又收购了 5,687 股。Emerald Advisers LLC 在第二季度将其在 Savara 的持仓增加了 14.4%。Emerald Advisers LLC 目前拥有 3,534,368 股该公司股票，价值 8,058,000 美元，此前在上个季度又收购了 444,155 股。Geode Capital Management LLC 在第二季度将其在 Savara 的持仓增加了 5.2%。Geode Capital Management LLC 目前拥有 2,970,183 股该公司股票，价值 6,773,000 美元，此前在上个季度又收购了 147,946 股。最后，Affinity Asset Advisors LLC 在第二季度购买了 Savara 的新股份，价值约为 1,140,000 美元。机构投资者持有该公司 87.93% 的股票。</p>
<h2>关于 Savara</h2>
<p>（获取免费报告）</p>
<p>Savara Inc（纳斯达克：SVRA）是一家临床阶段的生物制药公司，专注于开发和商业化针对罕见呼吸疾病的疗法。该公司专注于许可、推进并可能将新型治疗方案推向市场，以应对具有高度未满足医疗需求的严重肺部疾病。</p>
<p>该公司的主要候选药物 Molgradex（重组人粒细胞 - 巨噬细胞集落刺激因子，或 GM-CSF）正在接受监管审查，用于治疗自身免疫性肺泡蛋白沉积症（PAP），这是一种以表面活性剂积累为特征的罕见肺病。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Savara 更好</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解释</li>
<li>特朗普做了什么？？</li>
<li>崩盘前一个月</li>
<li>在 1 月 1 日投资 1,000 美元于这只股票 [不是 NVDA]</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元于 Savara 吗？</h2>
<p>在你考虑 Savara 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Savara 并不在名单上。</p>
<p>虽然 Savara 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

SVRA

<p>HC Wainwright 将 Savara Inc. 的 2029 财年每股收益预期从 0.51 美元上调至 0.56 美元，维持 “买入” 评级，目标价为 10.00 美元。该股票的共识评级为 “适度买入”，目标价为 9.13 美元。Savara 专注于罕见呼吸疾病的治疗，其主要候选药物正在接受监管审查。机构投资者持有该股票的 87.93%</p>

<p>Savara Inc. (NASDAQ:SVRA - Free Report) - Stock analysts at HC Wainwright increased their FY2029 earnings per share (EPS) estimates for shares of Savara in a note issued to investors on Tuesday, December 23rd. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.56 per share for the year, up from their prior forecast of $0.51. HC Wainwright currently has a &#34;Buy&#34; rating and a $10.00 target price on the stock. The consensus estimate for Savara's current full-year earnings is ($0.45) per share.</p>
<div class="lb-trans"><p>Savara Inc.（纳斯达克代码：SVRA - 免费报告）- HC Wainwright 的股票分析师在 12 月 23 日（星期二）向投资者发布的报告中上调了对 Savara 2029 财年每股收益（EPS）的预期。HC Wainwright 分析师 A. Fein 现在预计该公司将发布每股收益 0.56 美元，高于之前预测的 0.51 美元。HC Wainwright 目前对该股票给予 “买入” 评级，目标价格为 10.00 美元。市场普遍预计 Savara 当前全年的每股收益为（0.45 美元）。</p>
</div><p>Several other brokerages also recently weighed in on SVRA. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Savara in a report on Wednesday, October 8th. UBS Group set a $10.00 price objective on Savara in a research report on Tuesday. Guggenheim reiterated a &#34;buy&#34; rating on shares of Savara in a research report on Tuesday. Wells Fargo &amp; Company boosted their price target on Savara from $7.00 to $9.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, December 18th. Finally, Oppenheimer set a $10.00 price target on Savara in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $9.13.</p>
<div class="lb-trans"><p>其他几家券商最近也对 SVRA 发表了看法。Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对 Savara 股票的 “卖出（d-）” 评级。瑞银集团在周二的研究报告中将 Savara 的目标价格设定为 10.00 美元。Guggenheim 在周二的研究报告中重申了对 Savara 股票的 “买入” 评级。富国银行在 12 月 18 日（星期四）的报告中将 Savara 的目标价格从 7.00 美元上调至 9.00 美元，并给予该股票 “超配” 评级。最后，Oppenheimer 在周二的研究报告中将 Savara 的目标价格设定为 10.00 美元。一位研究分析师对该股票给予了强烈买入评级，七位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，共识目标价格为 9.13 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on SVRA</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 SVRA 股票分析</strong></p>
</div><h2>Savara Stock Performance</h2>
<div class="lb-trans"><h2>Savara 股票表现</h2>
</div><p>Shares of NASDAQ SVRA opened at $6.44 on Wednesday. The stock has a market cap of $1.31 billion, a PE ratio of -12.15 and a beta of 0.23. Savara has a 1 year low of $1.89 and a 1 year high of $7.01. The firm has a fifty day moving average price of $5.06 and a 200-day moving average price of $3.64. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.65 and a quick ratio of 7.65.</p>
<div class="lb-trans"><p>周三，纳斯达克 SVRA 的股票开盘价为 6.44 美元。该股票的市值为 13.1 亿美元，市盈率为-12.15，贝塔值为 0.23。Savara 的 1 年最低价为 1.89 美元，1 年最高价为 7.01 美元。该公司的 50 日移动平均价格为 5.06 美元，200 日移动平均价格为 3.64 美元。公司的债务与股本比率为 0.32，流动比率为 7.65，速动比率为 7.65。</p>
</div><p>Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01).</p>
<div class="lb-trans"><p>Savara（纳斯达克：SVRA - 获取免费报告）最后一次发布财报是在 11 月 12 日（星期三）。该公司报告的季度每股收益为（0.14 美元），低于市场共识预期的（0.13 美元）0.01 美元。</p>
</div><h2>Institutional Investors Weigh In On Savara</h2>
<div class="lb-trans"><h2>机构投资者对 Savara 的看法</h2>
</div><p>Large investors have recently bought and sold shares of the business. F m Investments LLC lifted its position in Savara by 41.2% during the second quarter. F m Investments LLC now owns 314,846 shares of the company's stock valued at $718,000 after purchasing an additional 91,830 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Savara by 17.6% in the 2nd quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company's stock valued at $87,000 after acquiring an additional 5,687 shares during the last quarter. Emerald Advisers LLC lifted its holdings in shares of Savara by 14.4% in the 2nd quarter. Emerald Advisers LLC now owns 3,534,368 shares of the company's stock valued at $8,058,000 after acquiring an additional 444,155 shares during the last quarter. Geode Capital Management LLC grew its position in Savara by 5.2% in the second quarter. Geode Capital Management LLC now owns 2,970,183 shares of the company's stock worth $6,773,000 after acquiring an additional 147,946 shares in the last quarter. Finally, Affinity Asset Advisors LLC bought a new stake in Savara during the second quarter worth approximately $1,140,000. Institutional investors own 87.93% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。F m Investments LLC 在第二季度将其在 Savara 的持仓增加了 41.2%。F m Investments LLC 目前拥有 314,846 股该公司股票，价值 718,000 美元，此前在上个季度又购买了 91,830 股。Farther Finance Advisors LLC 在第二季度将其在 Savara 的持仓增加了 17.6%。Farther Finance Advisors LLC 目前拥有 38,001 股该公司股票，价值 87,000 美元，此前在上个季度又收购了 5,687 股。Emerald Advisers LLC 在第二季度将其在 Savara 的持仓增加了 14.4%。Emerald Advisers LLC 目前拥有 3,534,368 股该公司股票，价值 8,058,000 美元，此前在上个季度又收购了 444,155 股。Geode Capital Management LLC 在第二季度将其在 Savara 的持仓增加了 5.2%。Geode Capital Management LLC 目前拥有 2,970,183 股该公司股票，价值 6,773,000 美元，此前在上个季度又收购了 147,946 股。最后，Affinity Asset Advisors LLC 在第二季度购买了 Savara 的新股份，价值约为 1,140,000 美元。机构投资者持有该公司 87.93% 的股票。</p>
</div><h2>About Savara</h2>
<div class="lb-trans"><h2>关于 Savara</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.</p>
<div class="lb-trans"><p>Savara Inc（纳斯达克：SVRA）是一家临床阶段的生物制药公司，专注于开发和商业化针对罕见呼吸疾病的疗法。该公司专注于许可、推进并可能将新型治疗方案推向市场，以应对具有高度未满足医疗需求的严重肺部疾病。</p>
</div><p>The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.</p>
<div class="lb-trans"><p>该公司的主要候选药物 Molgradex（重组人粒细胞 - 巨噬细胞集落刺激因子，或 GM-CSF）正在接受监管审查，用于治疗自身免疫性肺泡蛋白沉积症（PAP），这是一种以表面活性剂积累为特征的罕见肺病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Savara</li>
<li>The boring AI play that could pay up to $4,290 monthly</li>
<li>Trump’s “real estate deal for America” explained</li>
<li>Trump Did WHAT??</li>
<li>A month before the crash</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Savara 更好</li>
<li>可能每月支付高达 4,290 美元的无聊 AI 投资</li>
<li>特朗普的 “美国房地产交易” 解释</li>
<li>特朗普做了什么？？</li>
<li>崩盘前一个月</li>
<li>在 1 月 1 日投资 1,000 美元于这只股票 [不是 NVDA]</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1ZSQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=SVRA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Savara Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 Savara 吗？</h2>
</div><p>Before you consider Savara, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Savara 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Savara 并不在名单上。</p>
</div><p>While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Savara 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

HC Wainwright 发布了 Savara 公司 2029 财年的收益预估